PI3K-Akt/mTOR signaling is known to be hyperactivated in CTCL, and studies have shown the therapeutic potential of PI3K/mTOR inhibition in CTCL (Bresin et al., 2020). The gene discussed is AKT1; the disease is primary cutaneous T-cell non-Hodgkin lymphoma.